Literature DB >> 2051775

Intimal hyperplasia is reduced by ornithine decarboxylase inhibition.

E D Endean1, J F Kispert, K W Martin, W O'Connor.   

Abstract

Polyamines are intracellular cations that are thought to play a role in the regulation of cell growth and differentiation. This study was undertaken to determine if inhibition of ornithine decarboxylase (ODC), the rate-limiting enzyme of polyamine synthesis, suppresses formation of intimal hyperplasia (IH) after arterial injury. Twenty New Zealand white rabbits underwent balloon catheter deendothelialization of a common carotid artery. Treated animals (n = 10) were given alpha-difluoromethylornithine (DFMO), an inhibitor of ODC, ad lib in drinking water as a 2% solution. DFMO was begun 3 days prior to surgery and continued until vessel harvest. Vessels were perfusion-fixed at harvest, 2 (n = 10) and 4 (n = 10) weeks postoperatively. All arteries remained patent. There were no histologic differences in the IH between treated and untreated animals. The intima and media surface areas on serial arterial cross sections were determined using computer-assisted planimetry. There was a significant difference in the IH surface area of injured arteries between untreated and DFMO-treated animals at both 2 (17.6 +/- 2.0 vs 3.0 +/- 1.6 microns 2; P less than or equal to 0.001) and 4 weeks 27.4 +/- 5.6 vs 7.1 +/- 1.8 microns 2; P less than or equal to 0.008). No differences were seen in medial thickness. We conclude that ODC inhibition reduces early development of IH after arterial deendothelialization. These data support the hypothesis that polyamines may be cellular messengers involved in the regulation of IH formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051775     DOI: 10.1016/0022-4804(91)90054-p

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

Review 1.  Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Authors:  William Durante; Fruzsina K Johnson; Robert A Johnson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

2.  Arginase type I as a marker of coronary heart disease in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Vassilios Liakopoulos; Georgia Antoniadi; Ioannis Stefanidis; Grammati Galaktidou
Journal:  Int Urol Nephrol       Date:  2010-09-15       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.